This article addresses the metrics that Medical Affairs can use to measure how effectively they communicate on their strategic imperatives, with a specific focus on Share of Scientific Voice (SoSV).
This article addresses the metrics that Medical Affairs can use to measure how effectively they communicate on their strategic imperatives, with a specific focus on Share of Scientific Voice (SoSV).
10 reasons digital strategies fail plus ways you and your teams can navigate between the icebergs of these failures on the way to success.
The authors present planning, process, compliance, and copyright considerations for both author- and sponsor-led publication enhancers.
As evidence generation becomes more advanced and integrated into Medical Affairs strategic plans, there is a greater need to maximize its impact by leveraging emerging digital technologies to communicate complex clinical and nonclinical data.
This article provides top-level framework and broad conceptual categories for understanding digital structures within Medical Affairs and biopharmaceutical/MedTech organizations, helping leaders to make organizational decisions to drive their digital strategy with intention and purpose.
Based on discussions between 80 cross-industry Field Medical colleagues from small to large biopharmaceutical and medtech companies, this article highlights key actions for Medical Affairs teams to consider for implementation in their own organizations.
Medical technologies require equipping health care providers with the theoretical knowledge of best and safest use and also ensuring users’ practical competence. This article by the MAPS MedTech and External Education FAWGs overviews these best practices.
Digitalization offers Medical Affairs teams the opportunity to rethink strategy and actions across the lifecycle of traditional and nontraditional products.
There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for applications including regulatory decisions, health technology assessment (HTA), pharmacovigilance and more. However, Asia currently lacks a framework to effectively collect and utilize a broad range of RWD/RWE.